The US Food and Drug Administration (FDA) has approved the PASCAL Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER) in patients with degenerative mitral ...
IRVINE, Calif., Aug. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the ...
Transcatheter mitral valve repair with the PASCAL device showed high rates of survival and freedom from heart failure rehospitalization at 2 years in the single-arm, safety and efficacy CLASP study.
Edwards Lifesciences can say two things about its Pascal Precision Valve Repair System. The first is that the technology has FDA approval and the second is that in a study, the device showed its ...
Healthcare Asia on MSN
NUHCS unveils PASCAL TEER procedure for mitral valve disease
The treatment is an alternative to traditional open-heart surgery. The National University Heart Centre, Singapore (NUHCS) ...
TCT 748: Effects of SGLT2 Inhibitors on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus Undergoing Transcatheter Mitral Valve Repair: A Propensity-Matched Analysis ...
UC San Francisco interventional cardiologists and interventional echocardiographers recently performed two novel minimally invasive cardiac procedures for the first time in the health system.
Please provide your email address to receive an email when new articles are posted on . Patients with severe degenerative mitral regurgitation saw sustained benefits with a novel transcatheter edge-to ...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results